Recursion Pharmaceuticals

Recursion Pharmaceuticals Debt

The Debt of Recursion Pharmaceuticals (RXRX) as of Nov 22, 2026 is 77.97 M USD. In the previous year, Debt was 108.49 M USD — a change of -28.14% (lower).

Debt

77.97 MUSD

YoY

-28.14%

Last updated:

In 2025, Recursion Pharmaceuticals's total debt was 77.97 M USD, a -28.14% change from the 108.49 M USD total debt recorded in the previous year.

The Recursion Pharmaceuticals Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2019
16.17 M USD
Jan 1, 2020
15.66 M USD
Jan 1, 2021
11.48 M USD
Jan 1, 2022
51.01 M USD
Jan 1, 2023
50.67 M USD
Jan 1, 2024
108.49 M USD
Jan 1, 2025
77.97 M USD
The Recursion Pharmaceuticals Debt history
YEARDebtYoY
77.97 MUSD-28.14%
108.49 MUSD+114.11%
50.67 MUSD-0.65%
51.01 MUSD+344.37%
11.48 MUSD-26.71%
15.66 MUSD-3.14%
16.17 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Debt Details

Understanding Recursion Pharmaceuticals's Debt Structure

Recursion Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Recursion Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Recursion Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Recursion Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Recursion Pharmaceuticals stock

Debt of Recursion Pharmaceuticals is 77.97 M USD in 2025.

Debt of Recursion Pharmaceuticals changed from 108.49 M USD to 77.97 M USD, representing a -28.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Recursion Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Recursion Pharmaceuticals

All Key Metrics — Recursion Pharmaceuticals